POF Versus FOLFOX Plus IP Paclitaxel in AGC
The aim of this study was to compare the efficacy and safety of intravenous or intraperitoneal paclitaxel plus FOLFOX as first-line treatment in AGC with peritoneal metastases, a phase II Clinical trial.
Gastric Cancer
DRUG: POF|DRUG: FOLFOX plus PAC(ip)
Overall Survival(OS), The length of time from enrollment until the time of death, 12 months
Adverse Event（AE）, Adverse Event according to NCI CTCAE 5 criteria, 6month|Objective Overall Response Rate (ORR), Clinical response of treatment according to RESIST v1.1 criteria, 6month
The aim of this study was to compare the efficacy and safety of intravenous or intraperitoneal paclitaxel plus FOLFOX as first-line treatment in AGC with peritoneal metastases, a phase II Clinical trial.